JHS Svendgaard Laboratories Ltd
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of
oral and dental products for national and international brands[1]
- Market Cap ₹ 112 Cr.
- Current Price ₹ 13.2
- High / Low ₹ 32.9 / 11.0
- Stock P/E
- Book Value ₹ 20.2
- Dividend Yield 0.00 %
- ROCE -5.11 %
- ROE -10.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.65 times its book value
- Company is expected to give good quarter
- Debtor days have improved from 66.0 to 51.8 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -7.10% over past five years.
- Promoter holding is low: 34.6%
- Company has a low return on equity of -4.10% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.67%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 55 | 100 | 104 | 138 | 120 | 133 | 97 | 80 | 85 | 71 | 92 | |
39 | 59 | 93 | 92 | 122 | 111 | 123 | 93 | 80 | 94 | 72 | 96 | |
Operating Profit | -4 | -4 | 7 | 12 | 17 | 8 | 9 | 4 | 0 | -9 | -1 | -4 |
OPM % | -11% | -7% | 7% | 11% | 12% | 7% | 7% | 4% | 0% | -11% | -1% | -4% |
-3 | -6 | -17 | 0 | 32 | 5 | 1 | 6 | 8 | -7 | 4 | 0 | |
Interest | 14 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 |
Depreciation | 15 | 12 | 10 | 6 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 8 |
Profit before tax | -35 | -22 | -22 | 5 | 41 | 5 | 2 | 3 | 2 | -23 | -3 | -12 |
Tax % | -18% | 0% | 0% | -326% | 32% | 31% | 1% | 13% | 228% | -24% | 18% | 58% |
-29 | -22 | -22 | 22 | 28 | 4 | 2 | 3 | -2 | -18 | -4 | -20 | |
EPS in Rs | -11.95 | -9.19 | -5.75 | 4.98 | 4.61 | 0.59 | 0.29 | 0.43 | -0.38 | -2.70 | -0.52 | -2.31 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | -7% |
3 Years: | 5% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | -2% |
5 Years: | % |
3 Years: | % |
TTM: | -358% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | -4% |
3 Years: | -15% |
1 Year: | -42% |
Return on Equity | |
---|---|
10 Years: | 1% |
5 Years: | -2% |
3 Years: | -4% |
Last Year: | -11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 24 | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 |
Reserves | 21 | 78 | 63 | 91 | 116 | 119 | 121 | 127 | 125 | 96 | 92 | 88 |
54 | 19 | 2 | 2 | 2 | 7 | 3 | 2 | 2 | 3 | 5 | 6 | |
74 | 33 | 19 | 19 | 26 | 33 | 46 | 21 | 19 | 39 | 22 | 22 | |
Total Liabilities | 173 | 153 | 123 | 156 | 205 | 220 | 230 | 215 | 211 | 215 | 197 | 202 |
121 | 108 | 65 | 65 | 71 | 69 | 58 | 59 | 55 | 65 | 90 | 90 | |
CWIP | 0 | 0 | 1 | 1 | 0 | 5 | 7 | 9 | 16 | 9 | 1 | 0 |
Investments | 0 | 0 | 0 | 1 | 18 | 15 | 17 | 14 | 15 | 3 | 3 | 4 |
52 | 46 | 57 | 89 | 116 | 130 | 148 | 133 | 125 | 139 | 103 | 108 | |
Total Assets | 173 | 153 | 123 | 156 | 205 | 220 | 230 | 215 | 211 | 215 | 197 | 202 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
28 | 7 | -6 | -4 | 13 | -10 | 15 | 15 | -11 | 23 | -9 | -5 | |
3 | 1 | 4 | -3 | -27 | 1 | -7 | -6 | -1 | 10 | -22 | -20 | |
-29 | -10 | 4 | 10 | 14 | 4 | -8 | 6 | 0 | -1 | 2 | 23 | |
Net Cash Flow | 2 | -1 | 2 | 3 | 0 | -5 | -0 | 16 | -12 | 32 | -28 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60 | 82 | 25 | 48 | 113 | 171 | 262 | 221 | 74 | 80 | 66 | 52 |
Inventory Days | 122 | 94 | 53 | 96 | 59 | 51 | 19 | 76 | 104 | 128 | 177 | 71 |
Days Payable | 95 | 106 | 67 | 125 | 123 | 134 | 179 | 126 | 147 | 221 | 197 | 80 |
Cash Conversion Cycle | 87 | 70 | 12 | 19 | 48 | 88 | 101 | 171 | 31 | -13 | 46 | 42 |
Working Capital Days | -548 | -36 | 59 | 48 | 128 | 183 | 188 | 248 | 288 | 44 | 72 | 59 |
ROCE % | -11% | -14% | -3% | 5% | 9% | 4% | 7% | 2% | 1% | -2% | -2% | -5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
2d - Re-appointment of MD Nikhil Nanda from July 2, 2025; Independent Director Mukul Pathak tenure ended July 1, 2025.
-
Announcement under Regulation 30 (LODR)-Cessation
2d - Re-appointment of MD Nikhil Nanda; Independent Director Mukul Pathak's tenure ends; committee reconstituted.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On July 01, 2025
2d - Re-appointment of MD Nikhil Nanda and cessation of Independent Director Mukul Pathak effective July 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
25 Jun - Shareholders approved related party transactions, fund use alteration of Rs 30Cr, director reappointments, and loan to related entity.
- Closure of Trading Window 24 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Business Overview:[1]
JHSSLL manufactures Toothbrushes, Toothpastes, Mouthwash and Denture Tablets. Apart from working on its own brands viz. Dr. Gold, Aquawhite, etc. company also offers Contract Manufacturing Partnership to brands in domestic and international markets